

Index

18q deletion (18q-) syndrome, 128
47,XXY/47,XYY syndromes, 133

aceruloplasminemia, 123, 131
aciclovir, 194–5
acid maltase deficiency, 129
acquired (non-Wilsonian) hepatocerebral degeneration (ANWCHD), 186
acquired immunodeficiency syndrome (AIDS). *See* human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)
acute disseminated encephalomyelitis (ADEM), 150
Addison’s disease, 180
adenovirus encephalitis, 195
adrenal hormone disorders, 180–1
adrenomyeloneuropathy (AMN), 127
aging, normal, 12–13
agnosias, 8–9, 16, 27
akinetopsia, 9, 183
alcohol-related disorders, 184–6
Alexander’s disease, 127–8
alexia, 8
Alpers-Huttenlocher disease, 126
alpha-enolase antibodies, 157
alpha-galactosidase A, 129
aluminum, dialysate fluid levels, 184
Alzheimer’s disease (AD), 6, 24–9
 delirium episodes, 220
 depression and, 221
 diabetes mellitus association, 178
 disconnection syndrome conceptualization, 16
 essential tremor (ET) association, 125
 familial, 28–9
 frontal variant (fvAD), 24
 logopenic progressive aphasia, 27

- mild cognitive impairment (MCI)/prodromal AD, 29
- normal pressure hydrocephalus (NPH) differentiation, 170–1
- posterior cortical atrophy (PCA) pathology, 9, 24
- presymptomatic, 29
- seizures, 99
- Sjögren's syndrome differentiation, 153
- treatment, 28
- vascular dementia (VaD) differentiation, 73–4
- visual variant, 24
- amnesia, 5–6. *See also* memory
 - Alzheimer's disease (AD), 25
 - basal forebrain, 79
 - behavioural variant frontotemporal dementia (bvFTD), 31
 - craniopharyngioma, 168
 - diencephalic, 77
 - herpes simplex encephalitis (HSE), 194–5
 - hypoglycemia and acute, 178
 - limbic encephalitides, 156
 - lobectomy-related, 5–6, 97
 - migraine, 87
 - motor neurone disease (MND)/amyotrophic lateral sclerosis (ALS), 41
 - psychogenic, 222
 - strategic strokes, 77, 79
 - systemic lupus erythematosus (SLE), 152
 - transient epileptic (TEA), 88, 102–3
 - transient global (TGA), 88, 103
- amnesic shellfish poisoning, 187
- amyloid precursor protein (APP) gene mutations, 28–9, 84
- amylopectinosis, 131
- amyotrophic lateral sclerosis (ALS). *See* motor neurone disease (MND)/amyotrophic lateral sclerosis (ALS)
- Andersen's disease, 131
- Anderson-Fabry disease, 129
- androgen receptor gene mutations, 208
- anemia, pernicious, 181
- angioendotheliomatosis, 85
- angiogenin (ANG) mutations, 43
- angiokeratoma corporis diffusum, 129
- angular gyrus infarction, 77
- ANNA-3 antibodies, 156
- anomia, 35
- anterior communicating artery (AcoA) aneurysms, 79, 80
- anti-acetylcholine receptor (AChR) antibodies, 208
- antidepressant medication, 221
- anti-epileptic drugs (AEDs), cognitive impairment
 - causation, 98, 103–4
- anti-Hu antibodies, 156
- anti-Ma2 antibodies, 156
- anti-MuSK antibodies, 209
- anti-neutrophil cytoplasmic autoantibodies (ANCA), 155, 156
- antiphospholipid antibodies, 151, 152, 157
 - antiphospholipid antibody syndrome, 85, 86
- antiretroviral therapy, 198
- anti-striatal antibodies, 157
- antithyroid autoantibodies, 157
- anxiety disorders, 221–2
- aphasia, 7–8. *See also* language
 - acute disseminated encephalomyelitis (ADEM), 150
 - Alzheimer's disease (AD), 24, 27
 - behavioral variant frontotemporal dementia (bvFTD), 31–2
 - Broca's, 7
 - classification in frontotemporal lobar degenerations (FTLD), 30
 - conduction, 7, 16
 - epileptic, 103
 - multiple sclerosis (MS), 147–8, 150
 - post-stroke, 77
 - primary progressive (PPA), 30
 - lopogenic variant (LPA), 27
 - non-fluent (PNFA)/agrammatic variant, 32–4
 - semantic variant, 34–6
 - thalamic, 78
 - transcortical, 7, 24
 - Wernicke's, 7
- apnoea/hypopnoea index (AHI), 213–14
- apraxia 9. *See also* praxis,
 - Alzheimer's disease (AD), 25, 28
 - conceptual, 28
 - corticobasal degeneration, 49
 - Huntington's disease (HD), 112–14
 - ideomotor, 16
 - multiple sclerosis (MS), 147–8
 - of speech, 33–4
 - Parkinson's disease dementia (PDD)/dementia with Lewy bodies (DLB), 46, 48
 - progressive non-fluent aphasia (PNFA), 33–4
- aquaporin-4 antibodies, 150
- aqueduct stenosis, 169, 171
- arachnoid cyst, 172
- argyrophillic grain disease (AGD), 36–7
- arteriovenous fistula, intracranial dural (dAVF), 82

228 Index

- arteriovenous malformations (AVMs), 81
- arylsulfatase A (ARSA), 126
- aspirin, 152
- ataxia
 - ataxia telangiectasia (AT), 119
 - autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), 119
 - fragile X tremor/ataxia syndrome (FXTAS), 121
 - Friedreich's ataxia (FA), 118–19
 - spinocerebellar ataxias (SCA), 116–18
 - with vitamin E deficiency (AVED), 120
- ataxin-1 gene mutations, 117
- ataxin-2 gene mutations, 117
- ataxin-3 gene mutations, 117
- ataxin-7 gene mutations, 118
- ataxin-8 gene mutations, 118
- ATM* gene mutations, 119
- ATP 13A2* gene mutations, 123
- ATP7B* gene mutations, 121
- ATP-binding cassette (ABCD1) gene mutations, 127
- atrophin-1, 114
- attention, 2–4
 - Alzheimer's disease (AD), 25–6
 - basal ganglia support mechanism hypothesis, 14
 - behavioral variant frontotemporal dementia (bvFTD), 31
 - Huntington's disease (HD), 112–13
 - motor neurone disease (MND)/amyotrophic lateral sclerosis (ALS), 41
 - multiple sclerosis (MS), 146–7
 - Parkinson's disease dementia (PDD)/dementia with Lewy bodies (DLB), 46–7
 - progressive non-fluent aphasia (PNFA), 33
 - semantic dementia (SD), 34
- autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), 119
- azathioprine, 150
- A β -related angiitis (ABRA), 155
- bacterial meningitis, 197
- Balint's syndrome, 9, 127, 186
- Baltic myoclonus, 132
- basal forebrain infarction, 79
- basal ganglia, 14
- basophilic inclusion body disease (BIBD), 37
- Behçet's disease, neuro-Behçet's disease, 153
- beta-glucocerebrosidase deficiency, 130
- bilateral striatopallidodentate calcinosis, 124
- bilateral vestibulopathy, 158
- Binswanger's disease, 76–7
- bipolar disorder, 221
- blindsight, 9
- bone cysts, presenile dementia with, 115–16
- Borrelia burgdorferi*, 199
- bradyphrenia, 46
- brain tumors, 166–7
 - craniopharyngioma, 168
 - glioma and gliomatosis cerebri, 167
 - meningioma, 167
 - pituitary tumors, 167–8, 180
 - primary CNS lymphoma (PCNSL) and lymphomatosis cerebri, 168
 - radiotherapy and chemotherapy, 169
 - splenic tumors, 169
- brainstem
 - cognitive impairment and isolated lesions, 15
 - infarction, 79
- breathing disorders
 - carbon monoxide poisoning, 183
 - chronic obstructive pulmonary disease (COPD), 183
 - sleep-related, 212–15
- C9ORF72* hexanucleotide repeat mutations, 39–40, 43–4
- CACNA 1A* gene mutations, 87, 117
- CAG repeats, 111, 114
- callosal dementia, 15–16, 184, 186
- carbamazepine, 103–4
- carbon monoxide poisoning, 183
- cardiac surgery, cognitive impairment after, 75
- carotid artery disease, 16, 75
- carotid endarterectomy, 75
- caudate nucleus infarction, 78
- cavernous hemangiomas, 82
- celiac disease, 182
- central hypersomnias, 215
- central pontine myelinolysis, 184
- central sleep apnoea (CSA), 214–15
- cerebellar cognitive affective syndrome, 116
- cerebellar cognitive impairment, 15
- cerebellar infarction, 79
- cerebral amyloid angiopathies (CAA), 83–4
- cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 77, 82–5
- cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), 83
- cerebral vasculitides, 154–6
- cerebral visual motion blindness, 9
- cerebroside sulphate sulphotase, 126

- cerebrotendinous xanthomatosis (CTX), 131
 - ceruloplasmin gene mutations, 123
 - charged multivesicular body protein 2B (CHMP2B)
 - mutations, 38, 40, 43
 - chemotherapy, 169
 - chenodeoxycholic acid (CDA), 131
 - cholinesterase inhibitors (ChEIs). *See also specific drugs*
 - Alzheimer's disease (AD), 28
 - behavioral variant frontotemporal dementia (bvFTD), 32
 - carbon monoxide poisoning, 183
 - cerebral autosomal dominant arteriopathy with
 - subcortical infarcts and leukoencephalopathy (CADASIL), 77
 - epilepsy, 104
 - mild cognitive impairment (MCI), 29
 - multiple sclerosis (MS), 150
 - myasthenia gravis (MG), 209
 - narcolepsy, 215
 - Parkinson's disease dementia (PDD)/dementia with
 - Lewy bodies (DLB), 48
 - progressive supranuclear palsy (PSP), 49
 - vascular dementia (VaD), 77
 - Wernicke-Korsakoff syndrome (WKS), 185
- chorein, 122
- CHRNA4* gene mutations, 101
- CHRNA2* gene mutations, 101
- chromosome 3 linked frontotemporal dementia (FTD3), 40
- chronic inflammatory demyelinating polyneuropathy (CIDP), 158
- chronic kidney disease (CKD), 184
- chronic obstructive pulmonary disease (COPD), 183, 214
- chronic progressive external ophthalmoplegia (CPEO), 125–6
- Churg-Strauss syndrome, 154–6
- circadian rhythm sleep disorders, 215
- clipping, of aneurysms, 80
- CLN6* gene mutations, 130
- clobazam, 103
- clonazepam, 103, 216
- clonidine, 222
- cobalamin C disease, 182
- cobalamin deficiency, 181–2
- cognitive function
 - domains of, 1–11. *See also specific domains*
 - neuropsychological assessment, 11–12
- cognitive impairment
 - depression-related cognitive dysfunction, 220
 - mild. *See* mild cognitive impairment (MCI)
 - syndromes of, 12–16
 - vascular. *See* vascular cognitive impairment (VCI)
- coiling (intravascular embolization), 80
- collagen, excess deposition, 154
- colloid cyst, 171
- coma, 2
- congenital angiopathy, 83
- Conn's syndrome, 181
- consciousness, 2–3
 - fluctuations in dementia with Lewy bodies (DLB), 46
- continuous positive airway pressure (CPAP), 213–14
- coronary artery bypass graft (CABG), 75
- corpus callosum infarction, 77
- corticobasal degeneration (CBD), 49–50
- coxsackie virus encephalitis, 195
- craniopharyngioma, 168
- Creutzfeldt-Jakob disease (CJD)
 - familial (fCJD), 53
 - human growth hormone-related iatrogenic, 53
 - sporadic (sCJD), 51–2, 157
 - variant (vCJD), 52–3
- Cryptococcus neoformans*, 197
- Cushing's syndrome, 180
- cutaneous leukocytoclastic vasculitis, 155
- cystatin B gene mutations, 132
- cystatin C gene mutations, 84
- DAP12* gene mutations, 116
- de Grouchy syndrome, 128
- delirium, 2, 219–20
- dementia, 13–16
 - alcohol-related/alcohol-induced, 185–6
 - anti-epileptic drugs (AEDs) and, 103
 - callosal, 15–16, 184, 186
 - cortical vs. subcortical, 14–15
 - dementia pugilistica/sports-related head injury, 50–1
 - diagnostic criteria, 13–14
 - dialysis, 184
 - disconnection syndromes, 15–16
 - frontotemporal. *See* frontotemporal dementia (FTD)
 - hereditary, 111–16
 - hippocampal sclerosis, 38
 - HIV/AIDS, 198
 - hydrocephalic. *See* hydrocephalic dementias
 - limbic, 14
 - Marianas, 51
 - neurofibrillary tangle (NTD), 37
 - Parkinson's disease (PDD), 44–8
 - progressive supranuclear palsy (PSP), 48–9

- dementia (*cont.*)
- pseudodementia, 220
 - semantic (SD), 34–6, 194
 - strategic infarct, 77–9
 - thalamic, 15, 77
 - thiamine, 185
 - vascular. *See* vascular dementia (VaD)
 - with Lewy bodies (DLB), 9, 14, 45–8, 216
- dentatorubropallidolysian atrophy (DRPLA), 114–15
- depression, 220–1
- Devic's disease, 150
- diabetes mellitus, 177–8
- dialysis dementia, 184
- diaschisis, 14
- diffuse neurofibrillary tangles with calcification (DNTC), 37
- disconnection syndromes, 15–16, 146
- dissociative disorders, 222
- distractibility, 3
- domoic acid poisoning, 187
- donepezil
- alcohol-related dementia, 186
 - CADASIL, 83
 - epilepsy, 104
 - obstructive sleep apnoea-hypopnoea syndrome (OSAHS), 214
 - progressive supranuclear palsy (PSP), 49
 - vascular dementia (VaD), 77
- Down's syndrome, 99
- dural arteriovenous fistula (dAVF), intracranial, 82
- dystonia, 124–5
- dystrophin myotonic protein kinase (DMPK) gene mutations, 206
- DYT11, 124
- eIF2B* gene mutations, 128
- Ekbom's syndrome, 216
- electroconvulsive therapy (ECT), 102
- embolization, 80, 82
- encephalitides and meningoencephalitides, 194
- adenovirus encephalitis, 195
 - coxsackie virus encephalitis, 195
 - epilepsy and chronic encephalitis, 101–2
 - herpes simplex encephalitis (HSE), 194–5
 - herpes simplex type 2 encephalitis, 195
 - herpes zoster encephalitis (HZE), 195
 - human herpes virus-6 (HHV-6) infection, 195
 - Japanese encephalitis, 196
 - post-encephalitic parkinsonism (encephalitis lethargica), 196–7
 - rotavirus encephalitis, 196
 - subacute sclerosing panencephalitis (SSPE), 196
 - tick-borne encephalitis, 196
- endocrine disorders
- adrenal hormone disorders, 180–1
 - diabetes mellitus, 177–8
 - parathyroid disorders, 179–80
 - thyroid disorders, 178–9
- Engel's disease, 129
- epilepsy
- benign childhood epilepsy with centrotemporal spikes (BCECTS), 99
 - cognitive decline shared etiopathogenesis, 98–102
 - cognitive impairment and, 97–8
 - epileptic aphasia, 103
 - hereditary metabolic disorders, 130, 132
 - idiopathic generalized (IGE), 99
 - juvenile myoclonic epilepsy (JME), 99
 - localization-related (partial), 99–101
 - frontal lobe epilepsy (FLE), 101
 - autosomal dominant nocturnal (ADNFLE), 101
 - temporal lobe epilepsy (TLE), 100–1
 - myoclonic epilepsy and ragged red fibers (MERRF) syndrome, 125–6
 - Rasmussen's syndrome, 101–2
 - schizophrenia-like psychosis of (SLPE), 101, 220
 - seizures causing acquired cognitive impairment, 102–3
 - transient epileptic amnesia (TEA), 88, 102–3
 - treatment of cognitive problems, 104
- EPM2A/EPM2B* gene mutations, 132
- epsilon-sarcoglycan gene mutations, 124
- Erdheim-Chester disease, 158
- essential cryoglobulinemia, 155
- essential tremor (ET), 124–5, 216
- executive function, 10–11
- Alzheimer's disease (AD), 25, 28
 - behavioral variant frontotemporal dementia (bvFTD), 31, 32
 - Huntington's disease (HD), 112, 114
 - motor neurone disease (MND)/amyotrophic lateral sclerosis (ALS), 41–2
 - multiple sclerosis (MS), 147–8
 - Parkinson's disease dementia (PDD)/dementia with Lewy bodies (DLB), 46, 48
 - progressive non-fluent aphasia (PNFA), 33–4
 - semantic dementia (SD), 35–6

- extinction, 3
- extracellular matrix protein 1 (ECM1) gene mutations, 124
- Fabry's disease, 129
- Fahr's disease, 124
- familial encephalopathy with neuroserpin inclusion bodies (FENIB), 115
- familial British dementia (FBD), 115
- familial Danish dementia (FDD), 115
- familial hemiplegic migraine (FHM), 87–8
- familial occipital calcifications, hemorrhagic strokes, leukoencephalopathy, dementia and external carotid dysplasia (FOCHS-LADD), 84
- fatal familial insomnia (FFI), 53–4
- ferritin light polypeptide/ferritin light chain (FTL) gene mutations, 123
- fibromyalgia, 222–3
- FIG4* gene mutations, 43
- finger agnosia, 8
- Flynn effect, 4
- forgetting 7. *See also* amnesia; memory
- fornix infarction/lesions, 77, 171
- fragile site mental retardation 1 (FMR1) gene mutations, 121
- fragile X syndrome (FRAX), 121
- fragile X tremor/ataxia syndrome (FXTAS), 121
- frataxin gene mutations, 119
- Friedreich's ataxia (FA), 118–19
- frontotemporal dementia (FTD). *See also* frontotemporal lobar degenerations (FTLD)
 - amyotrophic lateral sclerosis (ALS) and, 40–1
 - behavioral variant (bvFTD), 30–2
 - chromosome 3 linked FTD, 40
 - diagnostic criteria, 14
 - inclusion body myopathy with Paget's disease and frontotemporal dementia (IBMPFD), 40, 171
 - with parkinsonism linked to chromosome 17 (FTDP-17), 39–40
- frontotemporal lobar degenerations (FTLD)
 - argyrophilic grain disease (AGD), 36–7
 - basophilic inclusion body disease (BIBD), 37
 - behavioral variant frontotemporal dementia (bvFTD), 30–2
 - diffuse neurofibrillary tangles with calcification (DNTC), 37
 - familial, 38–40
 - neurofibrillary tangle dementia (NTD), 37
 - neuronal intermediate filament inclusion disease (NIFID), 37–8
 - overview, 29–30, 36
 - progressive non-fluent aphasia (PNFA), 32–4
 - progressive subcortical gliosis (PSG) (of Neumann), 38
 - pure hippocampal sclerosis/hippocampal sclerosis dementia, 38
 - semantic dementia (SD), 34–6
- fukutin-related protein, 207
- fungal meningitis, 197
- fused in sarcoma (FUS) protein, 37–9, 43
- gabapentin, 104
- galactocerebroside β -galactosidase (GALC), 128
- galantamine, 77, 104
- gambling, pathological, 32, 48
- gastrointestinal diseases, 181–2
- Gaucher's disease, type III, 130
- general intelligence. *See* intelligence (general)/IQ
- genu of the internal capsule infarction, 78
- Gerstmann syndrome, 8, 9, 27, 152, 154–5
- Gerstmann-Straussler-Scheinker disease (GSS), 53
- giant cell arteritis (GCA), 154–5
- Glasgow Coma Scale (GCS), 3
- glatiramer acetate, 150
- glial fibrillary acidic protein (GFAP), 127
- glioma, 167
- gliomatosis cerebri, 167
- globoid cell leukodystrophy, 128
- globus pallidus infarction, 78
- glucose tolerance, impaired, 177–8
- gluten sensitivity, 182
- glycogen branching enzyme (GBE) deficiency, 131
- glycogen storage disease type IV (GSDIV), 131
- glycogenesis type IIb, 129
- GM2 gangliosidosis, 129–30
- granulomatous angiitis (primary angiitis of the CNS (PACNS)), 154–5
- Graves' disease, 179
- Hashimoto's encephalopathy (HE), 157
- head injury, sports-related, 50–1
- head turning sign, 12
- hemangiomas, cavernous, 82
- hemochromatosis, 131
- hemodynamic dementia, 74
- Henoch-Schonlein purpura, 155
- hepatolenticular degeneration (Wilson's disease), 121–2
- hereditary ataxias 116–20. *See also specific disorders*
- hereditary cerebral hemorrhage with amyloidosis Dutch type (HCHWA-D), 84

232 Index

- hereditary cerebral hemorrhage with amyloidosis
 - Icelandic type (HCHWA-I), 84
- hereditary dementia 111–16. *See also specific disorders*
- hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS), 128–9
- hereditary dystonic lipidosis, 129
- hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS), 84
- hereditary metabolic disorders
 - cerebrotendinous xanthomatosis (CTX), 131
 - hemochromatosis, 131
 - Lafora body disease, 132
 - leukodystrophies, 126–9
 - lysosomal storage disorders, 129–30
 - mitochondrial disorders, 125–6
 - myoclonic epilepsy of Unverricht and Lundborg, 132
 - polyglucosan body disease (PGBD), 131–2
 - porphyria, 132
- hereditary movement disorders
 - aceruloplasminemia, 123, 131
 - dystonia, 125
 - essential tremor (ET), 124–5
 - Fahr's disease, 124
 - fragile X syndrome (FRAX)/fragile X tremor/ataxia syndrome (FXTAS), 121
 - Kufor-Rakeb syndrome, 123–4
 - myoclonus-dystonia syndrome (MDS), 124
 - neuroacanthocytosis, 122–3
 - neurodegeneration with brain iron accumulation (NBIA)/pantothenate-kinase associated neurodegeneration (PKAN), 122
 - neuroferritinopathy, 123
 - Urbach-Wiethe disease, 124
 - Wilson's disease, 121–2
- hereditary multi-infarct dementia of Swedish type, 84–5
- hereditary spastic paraplegia (HSP), 120
- heredopathia ophthalmoto-encephalica, 115
- herpes simplex encephalitis (HSE), 194–5
- herpes simplex type 2 encephalitis, 195
- herpes zoster encephalitis (HZE), 195
- hexosaminidase A deficiency, 129
- highly active retroviral therapy (HAART), 198
- hippocampus
 - hippocampal infarction, 78–9
 - hippocampal sclerosis (pure)/hippocampal sclerosis dementia, 38
 - memory function and, 5, 97–8
- histiocytosis, 158
- homocystinuria, 182
- HTLV-1, 198–9
- HTRA1* gene, 83
- Hughes' syndrome (primary antiphospholipid antibody syndrome), 85–6
- human growth hormone-related iatrogenic
 - Creutzfeldt-Jakob disease, 53
- human herpes virus-6 (HHV-6) infection, 195
- human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), 197–8
 - HIV/AIDS dementia, 198
 - HIV-associated neurocognitive disorder (HAND), 198
 - HTLV-1, 198–9
 - progressive multifocal leukoencephalopathy (PML), 198
- Huntington's disease-like (HDL) syndromes, 53, 112, 118
- Huntington's disease (HD), 111–14
- hydrocephalic dementias, 169–71
 - aqueduct stenosis, 169, 171
 - colloid cyst and fornix lesions, 171
 - normal pressure hydrocephalus (NPH), 169–71
 - Paget's disease of bone, 171–2
- hyperaldosteronism, primary, 181
- hypercortisolism, 180
- hyperglycemia, 177–8
- hyperinsulinemia, 177
- hyperparathyroidism, 180
- hyperthyroidism, 179
- hypocortisolism, 180
- hypoglycemia, 178
- hypoparathyroidism, 179–80
- hypoperfusion dementia, 74
- hypothyroidism, 178–9
- immunosuppressive therapy, 150, 155–6
- inclusion body myopathy with Paget's disease and frontotemporal dementia (IBMPFD), 40, 171
- infective disorders
 - encephalitides and meningoencephalitides, 194–7
 - HIV and related disorders, 197–9
 - meningitides, 197
 - neuroborreliosis, 199–200
 - neurocysticercosis, 200
 - neurosyphilis, 199
 - tuberculosis/tuberculous meningitis, 200
 - Whipple's disease, 200–1
- intelligence (general)/IQ, 4–5
 - Alzheimer's disease (AD), 25–6
 - behavioral variant frontotemporal dementia (bvFTD), 31
 - epilepsy, 101–2

- motor neurone disease (MND)/amyotrophic lateral sclerosis (ALS), 41
- multiple sclerosis (MS), 147
- Parkinson's disease dementia (PDD)/dementia with Lewy bodies (DLB), 46–7
- progressive non-fluent aphasia (PNFA), 33
- semantic dementia (SD), 34–5
- interferon beta-1a/beta-1b, 150
- intermediate filament (IF) proteins, 37–8
- intracranial hypotension, spontaneous (SIH), 172–3
- intracranial vasculitis (primary angiitis of the CNS (PACNS)), 154–5
- intravascular lymphomatosis, 85
- iron metabolism abnormalities, 131
- IT15* gene mutations, 111
- ITM2B* gene mutations, 84, 115
- ITPR1* gene mutations, 118
- Japanese encephalitis, 196
- Kawasaki disease, 155
- Kearns-Sayre syndrome (KSS), 125–6
- Kennedy's syndrome, 208
- Kleine-Levin syndrome, 215
- Klinefelter syndrome, 133
- Kosaka-Shibayama disease, 37
- Krabbe disease, 128
- Kufor-Rakeb syndrome, 123–4
- Kufs disease, 130
- kuru, 52
- lacosamide, 104
- lacunar state, 76–7
- Lafora body disease, 132
- lamotrigine, 104
- Langerhans cell histiocytosis (LCH), 158
- language, 7–8. *See also* aphasia
 - Alzheimer's disease (AD), 25–7
 - behavioral variant frontotemporal dementia (bvFTD), 31–2
 - Huntington's disease (HD), 112–13
 - motor neurone disease (MND)/amyotrophic lateral sclerosis (ALS), 41–2
 - multiple sclerosis (MS), 147–8, 150
 - Parkinson's disease dementia (PDD)/dementia with Lewy bodies (DLB), 46–7
 - progressive non-fluent aphasia (PNFA), 33–4
 - semantic dementia (SD), 35
- Leber's hereditary optic neuropathy (LHON), 126
- Leigh syndrome, 126
- leukoencephalopathy, 169
- leukodystrophies, 126–9
 - 18q deletion (18q-) syndrome, 128
 - Alexander's disease and Rosenthal fiber encephalopathy (RFE), 127–8
 - hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS), 128–9
 - Krabbe disease, 128
 - metachromatic leukodystrophy (MLD), 126–7
 - Pelizaeus-Merzbacher disease (PMD), 128
 - vanishing white matter disease (VWMD), 128
 - X-linked adrenoleukodystrophy (X-ALD), 127
- levetiracetam, 104
- LG11 non-paraneoplastic limbic encephalitis (NPLE), 156–7
- limb-girdle muscular dystrophy (LGMD), 207–8
- limbic encephalitides, 156–7
- lipoid proteinosis, 124
- lobectomy, effects on memory function, 5–6, 97
- Löwenberg-Hill syndrome, 128
- Lyme disease, 199–200
- lymphoma, primary CNS (PCNSL), 168
- lymphomatosis cerebri, 168
- lysosomal storage disorders, 129–30
- lytico-bodig, 51
- Machado-Joseph disease (MJD), 117
- manganese poisoning/manganism, 186
- Marchiafava-Bignami disease, 186
- Marianas dementia, 51
- maspardin gene mutations, 120
- Mast syndrome, 120
- McArdle's disease, 208
- mefloquine, 198
- memantine, 28, 48, 77, 150
- memory, 5–7. *See also* amnesia
 - Alzheimer's disease (AD), 25–6
 - behavioral variant frontotemporal dementia (bvFTD), 31
 - brain tumors, 167–8
 - epilepsy, 98, 100–3
 - Huntington's disease (HD), 112–13
 - lobectomy effects, 5–6, 97
 - long term, 3, 5
 - motor neurone disease (MND)/amyotrophic lateral sclerosis (ALS), 41
 - multiple sclerosis (MS), 147

- memory (*cont.*)
- Parkinson's disease dementia (PDD)/dementia with Lewy bodies (DLB), 46–7
 - progressive non-fluent aphasia (PNFA), 33
 - semantic dementia (SD), 34–5
 - short term, 3, 5
 - working, 3, 5
- meningioma, 167
- meningitides, 197
- bacterial meningitis, 197
 - fungal meningitis, 197
 - tuberculous meningitis, 200
 - viral meningitis, 197
- meningoencephalitis. *See* encephalitis and meningoencephalitis
- metabolic disorders, 181
- gastrointestinal disease, 181–2
 - hereditary. *See* hereditary metabolic disorders
 - renal and electrolyte disorders, 184
 - respiratory disorders, 183
- metachromatic leukodystrophy (MLD), 126–7
- methylmalonic aciduria, 182
- microscopic polyangiitis, 155–6
- microtubule associated protein tau (MAPT) mutations, 38, 39–40
- migraine, 87–8, 216
- mild cognitive impairment (MCI) 13. *See also* vascular cognitive impairment
- multiple system atrophy (MSA), 50
 - Parkinson's disease (PD), 45
 - prodromal Alzheimer's disease (AD), 29
- Mills' syndrome, 43
- Mini-Mental State Examination (MMSE), 3
- mitochondrial disorders, 125–6
- mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome (MELAS), 125–6
 - mitochondrial neurogastrointestinal encephalopathy (MNGIE), 126
- MMACHC* gene mutations, 182
- modafinil, 215
- Modified Wisconsin Card Sorting Test (MWCST), 10
- mood disorders, 220–1
- motor neurone disease (MND)/amyotrophic lateral sclerosis (ALS), 40–2
- ALS/parkinsonism-dementia complex (ALS/PDC) of Guam, 51
 - familial ALS, 43–4
 - frontotemporal dementia (FTD) and, 40–1
 - Mills' syndrome variant, 43
 - primary lateral sclerosis (PLS) variant, 42
 - progressive muscular atrophy (PMA) variant, 43
- movement disorders
- hereditary. *See* hereditary movement disorders
 - sleep-related, 44, 216
- moyamoya, 85–6
- mucopolysaccharidosis III, 130
- multi-infarct dementia (MID), 74
- multiple sclerosis (MS), 16, 145–50
- multiple system atrophy (MSA), 50, 216
- muscular dystrophy
- limb-girdle (LGMD), 207–8
 - oculopharyngeal (OPMD), 208
- myasthenia gravis (MG), 208–9
- Mycobacterium tuberculosis*, 200
- mycophenolate, 150
- myelin basic protein (MBP) gene mutations, 128
- myelinolysis, central pontine (and extrapontine), 184
- myoclonic epilepsy and ragged red fibers (MERRF) syndrome, 125–6
- myoclonic epilepsy of Unverricht and Lundborg, 132
- myoclonus-dystonia syndrome (MDS), 124
- myophosphorylase deficiency, 208
- myotonic dystrophy, 206–7
- narcolepsy, 215
- NARP syndrome, 126
- Nasu-Hakola disease, 115–16, 124
- natalizumab, 150, 198
- National Adult Reading Test (NART), 4
- neglect, 3–4
- neuroacanthocytosis, 122–3
- neuro-Behçet's disease, 153
- neuroborreliosis, 199–200
- neurocutaneous syndromes (hereditary), 132–3
- neurocysticercosis, 200
- neurodegeneration with brain iron accumulation (NBIA), 122
- neurodegenerative disease. *See also specific diseases*
- terminology, 24
- neuroferritinopathy, 123
- neurofibrillary tangles (NFTs)
- Alzheimer's disease, 24, 25
 - diffuse neurofibrillary tangles with calcification (DNFC), 37
 - myotonic dystrophy, 207
 - neurofibrillary tangle dementia (NTD)/neurofibrillary tangle-predominant dementia (NFTPD), 37
- neurofibromatosis, 132–3

- neuroimaging, multiple sclerosis (MS), 148–9
- neuromuscular disorders, 206
 - limb-girdle muscular dystrophy (LGMD), 207–8
 - McArdle's disease, 208
 - myasthenia gravis (MG), 208–9
 - myotonic dystrophy, 206–7
 - oculopharyngeal muscular dystrophy (OPMD), 208
 - spinal and bulbar muscular atrophy (SBMA), 208
- neuromyelitis optica (NMO), 150
- neuronal ceroid lipofuscinosis (NCL), 130
- neuronal intermediate filament inclusion disease (NIFID), 37–8
- neuropsychological assessment
 - 'bedside', 11–12
 - formal, 11
- neurosarcoidosis, 150–1
- neuroserpin gene mutations, 115
- neurosyphilis, 199
- niacin deficiency, 182
- Niemann-Pick disease type C, 130
- Nitzschia pungens*, 187
- NMDA-R non-paraneoplastic limbic encephalitis (NPLE), 156–7
- non-paraneoplastic limbic encephalitis (NPLE), 156–7
- normal pressure hydrocephalus (NPH), 169–71
- notch3 protein mutations, 82
- NPC1/NPC2* gene mutations, 130
- obsessive-compulsive disorder (OCD), 221–2
- obstructive sleep apnoea-hypopnoea syndrome (OSAHS), 213–14
- oculopharyngeal muscular dystrophy (OPMD), 208
- olivopontocerebellar atrophy (OPCA), 50
- optineurin (OPTN) mutations, 43
- osmotic demyelination syndrome, 184
- osteitis deformans (Paget's disease), 40, 171–2
- oxcarbazepine, 104
- Paget's disease, 40, 171–2
- pain disorders, 222–3
- pantothenate-kinase-associated neurodegeneration (PKAN), 122
- paraneoplastic limbic encephalitis (PNLE), 156
- parasomnias, 216
- parathyroid disorders, 179–80
- PARK9, 123–4
- Parkinson's disease (PD)
 - essential tremor (ET) association, 125
 - mild cognitive impairment (MCI), 13, 45
 - Parkinson's disease dementia (PDD), 44–8
 - sleep disorders, 44, 216
- parkinsonian syndromes, 44
 - amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS/PDC) of Guam, 51
 - corticobasal degeneration (CBD), 49–50
 - dementia pugilistica/sports-related head injury, 50–1
 - dementia with Lewy bodies (DLB), 14, 45–8, 216
 - frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), 39–40
 - multiple system atrophy (MSA), 50, 216
 - myasthenia gravis (MG) and parkinsonism, 209
 - Parkinson's disease. *See* Parkinson's disease (PD)
 - post-encephalitic parkinsonism, 196–7
 - progressive supranuclear palsy (PSP), 48–9
- paroxetine, 32
- pediatric autoimmune neuropsychiatric disorders
 - associated with streptococcal infections (PANDAS), 157–8
- Pelizaeus-Merzbacher disease (PMD), 128
- pellagra, 182
- perception, 8–9
 - Alzheimer's disease (AD), 25, 27–8
 - behavioral variant frontotemporal dementia (bvFTD), 31–2
 - Huntington's disease (HD), 112–13
 - motor neurone disease (MND)/amyotrophic lateral sclerosis (ALS), 41–2
 - multiple sclerosis (MS), 147–8
 - Parkinson's disease dementia (PDD)/dementia with Lewy bodies (DLB), 46–7
 - progressive non-fluent aphasia (PNFA), 33–4
 - semantic dementia (SD), 35–6
- periodic limb movement disorder (PLMD), 216
- phakomatoses, 132–3
- phenytoin, 103–4
- phosphorylase, glycogen, muscle (PYGM) gene mutations, 208
- Pick's disease, terminology, 30
- pituitary tumors, 167–8, 180
- poly(A) binding protein II gene mutations, 208
- polyarteritis nodosa, 154–5
- polychondritis, relapsing, 154
- polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOS), 115–16, 124
- polycythemia rubra vera, 86
- polyglucosan body disease (PGBD), 131–2
- Pompe's disease, 129

- porphyria, 132
- postcardiac surgery cognitive impairment, 75
- post-encephalitic parkinsonism, 196–7
- posterior cortical atrophy (PCA), 9, 24, 27
- PPP 2R2B* gene mutations, 118
- praxis 9. *See also* apraxia
 - Alzheimer's disease (AD), 25, 28
 - behavioral variant frontotemporal dementia (bvFTD), 31, 32
 - Huntington's disease (HD), 112–14
 - motor neurone disease (MND)/amyotrophic lateral sclerosis (ALS), 41–2
 - multiple sclerosis (MS), 147–8
 - Parkinson's disease dementia (PDD)/dementia with Lewy bodies (DLB), 46–8
 - progressive non-fluent aphasia (PNFA), 33–4
 - semantic dementia (SD), 35–6
- prednisolone, 152–3, 173
- presenile dementia with bone cysts, 115–16
- presenilin gene mutations, 28–9
- pre-stroke dementia, 75
- primary angiitis of the CNS (PACNS), 154–5
- primary CNS lymphoma (PCNSL), 168
- primary lateral sclerosis (PLS), 42
- primidone, 104
- prion diseases
 - iatrogenic, 52–3
 - inherited, 53–4
 - overview, 51
 - sporadic Creutzfeldt-Jakob disease (sCJD), 51–2, 157
- PRNP* gene mutations, 53, 112
- progranulin (GRN) mutations, 38–40
- progressive multifocal leukoencephalopathy (PML), 198
- progressive muscular atrophy (PMA), 43
- progressive subcortical gliosis (PSG) (of Neumann), 38
- progressive supranuclear palsy (PSP), 14, 48–9
- progressive symmetric spinobulbar spasticity, 42
- prosaposin gene mutations, 126
- prosopagnosia, 8
- proteinopathy, terminology, 24
- proteolipid protein (PLP) gene mutations, 128
- proximal myotonic myopathy (PROMM), 206–7
- pseudodementia, 220
- psychiatric disorders, 219
 - anxiety disorders, 221–2
 - delirium, 219–20
 - dissociative disorders, 222
 - mood disorders, 220–1
 - schizophrenia, 220
 - psychogenic amnesia, 222
 - psychomotor speed, epilepsy, 98
 - psychosis, schizophrenia-like, 220
- pumphead, 75
- pure alexia, 8
- pure hippocampal sclerosis, 38
- pure word blindness, 8
- pure word deafness, 8, 16
- radiotherapy, 169
- rapid eye movement sleep behavior disorder (REMSBD), 44, 216
- Rasmussen's syndrome, 101–2
- reboxetine, 185
- relapsing polychondritis, 154
- renal failure, 184
- respiratory disorders. *See* breathing disorders
- restless legs syndrome (RLS), 216
- rheumatoid arthritis (RhA), 154–5
- Ricker's syndrome, 206–7
- risk-taking behavior, 32
- rituximab, 150
- rivastigmine, 48, 215
- Rosai-Dorfman disease, 158
- Rosenthal fiber encephalopathy (RFE), 127–8
- rotavirus encephalitis, 196
- sacsin gene mutations, 119
- Sanfilippo syndrome, 130
- saposin B deficiency, 126
- sarcoidosis, neurosarcoidosis, 150–1
- schizophrenia, 220
- schizophrenia-like psychosis, 101, 220
- scleroderma, 154
- semantic dementia (SD), 34–6
- senile dementia with tangles (neurofibrillary tangle dementia (NTD)), 37
- sex chromosome aneuploides, 133
- shift-work sleep disorder (SWSD), 215
- Shy-Drager syndrome, 50
- sickle cell disease, 86
- sinus histiocytosis with massive lymphadenopathy, 158
- Sjögren's syndrome, 152–3
- sleep-related disorders, 212
 - breathing disorders, 212–15
 - central hypersomnias, 215
 - circadian rhythm sleep disorders, 215
 - movement disorders, 44, 216
 - parasomnias, 216

- Sneddon's syndrome, 86
sodium valproate, 103
solvent exposure, 187
spastin gene mutations, 120
Spatz-Lindenberg disease, 86
SPG21 (Mast syndrome), 120
SPG4, 120
spinal and bulbar muscular atrophy (SBMA), 208
spinocerebellar ataxias (SCA), 116–18
splenial tumors, 169
spontaneous intracranial hypotension (SIH), 172–3
sports-related head injury, 50–1
Steele-Richardson-Olszewski (SRO) syndrome
 (progressive supranuclear palsy (PSP)), 14, 48–9
Steinert's disease, 206–7
steroids, 149, 157, 194. *See also specific drugs*
strategic infarct dementia, 77–9
striatonigral degeneration (SND), 50
strokes, strategic, 77–9
Stroop Test, 10
subacute sclerosing panencephalitis (SSPE), 196
subarachnoid hemorrhage (SAH), 79–80
 aneurysmal, 79–80
 perimesencephalic (non-aneurysmal), 80–1
 superficial siderosis of the nervous system, 81
subcortical arteriosclerotic encephalopathy (SAE)
 (Binswanger's disease), 76–7
subcortical ischemic vascular dementia (SIVD), 76
subdural hematoma (SDH), 172
superficial siderosis of the nervous system, 81
superoxide dismutase-1 (SOD1) mutations, 43–4
Susac syndrome, 86–7
Sydenham's chorea, 157–8
synucleinopathies, 45
syphilis, neurosyphilis, 199
systemic lupus erythematosus (SLE), 151–2
systemic sclerosis, 154
systemic vasculitides, 154–6

Taenia solium, 200
Takayasu's arteritis, 154–5
TAR-DNA binding protein 43 (TDP-43) mutations, 38, 43
TATA box-binding protein (TBP) gene mutations, 112, 118
Tay-Sachs disease, 129–30
thalamus
 thalamic dementia, 15, 77
 thalamic infarction, 77–8

thyroid disorders, 157, 178–9
thyroid stimulating hormone (TSH), 179
tiagabine, 104
ticks
 neuroborreliosis, 199
 tick-borne encephalitis, 196
topiramate, 104
Tourette syndrome (TS), 221–2
toxin-related disorders, 184–7
transient epileptic amnesia (TEA), 88, 102–3
transient global amnesia (TGA), 88, 103
TREM2 gene mutations, 116
Tropheryma whippelii, 200
tropical spastic paraparesis (TSP), 198
TSC1/TSC2 gene mutations, 133
tuberculosis/tuberculous meningitis, 200
tuberous sclerosis, 133
Turner syndrome, 133
TYROBP gene mutations, 116

ubiquilin 2 (UBQLN2) mutations, 39, 43
Urbach-Wiethe disease, 124

valosin-containing protein (VCP) mutations, 38, 40, 43, 172
vanishing white matter disease (VWMD), 128
VAPB gene mutations, 43
varicella zoster virus (VZV), 195
vascular cognitive impairment (VCI), 13, 73–4
 CADASIL, 83–4
 disorders of possible vascular etiology, 87–8
 subarachnoid hemorrhage (SAH), 79–81
 vascular malformations, 81–2
 vasculopathies, 82–7
vascular dementia (VaD), 73–4
 cortical, 74–5
 Fabry's disease, 129
 strategic infarct dementia, 77–9
 subarachnoid hemorrhage (SAH), 80
 subcortical, 76
 vascular malformations, 81–2
 vasculopathies, 82–7
vascular malformations, intracranial, 81–2
vasculitides, 154–6
vasculopathies, 82–7
 cerebral amyloid angiopathies (CAA), 83–4
 cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 77, 82–5

vasculopathies (<i>cont.</i>)	vitamin B group deficiencies
cerebral autosomal recessive arteriopathy with	pellagra, 182
subcortical infarcts and leukoencephalopathy	vitamin B1 (thiamine), 185
(CARASIL), 83	vitamin B ₁₂ , 181–2
hereditary endotheliopathy with retinopathy,	vitamin E deficiency, ataxia with (AVED), 120
nephropathy, and stroke (HERNS), 84	von Economo disease, 196–7
hereditary multi-infarct dementia of Swedish type,	von Winiwarter-Buerger's disease, 86
84–5	VPS13A gene mutations, 122
Hughes' syndrome, 85–6	
intravascular lymphomatosis, 85	watershed infarction, 74
moyamoya, 85–6	Wechsler Intelligence Scales, 4
polycythemia rubra vera, 86	Wegener's granulomatosis, 154–6
Sneddon's syndrome, 86	Wernicke-Korsakoff syndrome (WKS), 52, 184–5
Spatz-Lindenberg disease, 86	Whipple's disease, 200–1
Susac syndrome, 86–7	Wilson's disease, 121–2
venous sinus thrombosis, 87	Wisconsin Card Sorting Test (WCST), 148
venous sinus thrombosis, 87	Worster-Drought syndrome, 115
vestibulopathy, bilateral, 158	
vigabatrin, 104	X-linked adrenoleukodystrophy (X-ALD), 127
viral meningitis, 197	
visual agnosia, 8–9, 27	zinc finger protein-9 (ZNF9) gene mutations, 206
visual neglect, 3	zonisamide, 104